Influenza A/H1N1v: monitoring of adverse reactions related to the vaccine Pandemrix

As part of the national campaign of vaccination against influenza virus A/H1N1v, the Federal Agency for Medicines and Health Products (FAMHP) has implemented a programme to monitor adverse reactions of the vaccine used in Belgium (Pandemrix). This programme fits into the European risk management plan and completes it. A first report is now available

See other languages (French or Dutch)

Contact for the press : comm@fagg-afmps.be
Contact for the health professionals : adversedrugreactions@fagg-afmps.be
Contact for the patients : patientinfo@fagg-afmps.be

Report of 4th December 2009 concerning the adverse reactions of the Pandemrix vaccine against the influenza A/H1N1v virus (period from 18/10/2009 until 31/11/2009) (French version)

 

 

 

 

 

 

 

 

Last updated on
09/12/2009